Literature DB >> 33724066

Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial.

Martijn R Meijerink1, Alette H Ruarus1, Laurien G P H Vroomen1, Robbert S Puijk1, Bart Geboers1, Sanne Nieuwenhuizen1, Bente A T van den Bemd1, Karin Nielsen1, Jan J J de Vries1, Krijn P van Lienden1, Birgit I Lissenberg-Witte1, M Petrousjka van den Tol1, Hester J Scheffer1.   

Abstract

Background Irreversible electroporation (IRE), an ablative technique that uses high-voltage electrical pulses, has shown promise for eradicating tumors near critical structures, including blood vessels and bile ducts. Purpose To investigate the efficacy and safety of IRE for colorectal liver metastases (CRLMs) unsuitable for resection or thermal ablation because of proximity to critical structures and for further systemically administered treatments. Materials and Methods Between June 2014 and November 2018, participants with fluorine 18 (18F) fluorodeoxyglucose (FDG) PET-avid CRLMs measuring 5.0 cm or smaller, unsuitable for partial hepatectomy and thermal ablation, underwent percutaneous or open IRE (ClinicalTrials.gov identifier: NCT02082782). Follow-up included tumor marker assessment and 18F-FDG PET/CT imaging. For the primary end point to be met, at least 50% of treated participants had to be alive without local tumor progression (LTP) at 12 months, defined as LTP-free survival. Secondary aims were safety, technical success, local control allowing for repeat procedures, disease-free status, and overall survival. Results A total of 51 participants (median age, 67 years [interquartile range, 62-75 years]; 37 men) underwent IRE. Of these 51 participants, 50 with a total of 76 CRLMs (median tumor size, 2.2 cm; range, 0.5-5.4 cm) were successfully treated in 62 procedures; in one participant, treatment was stopped prematurely because of pulse-induced cardiac arrhythmia. With a per-participant 1-year LTP-free survival of 68% (95% CI: 59, 84) according to competing risk analysis, the primary end point was met. Local control following repeat procedures was achieved in 74% of participants (37 of 50). Median overall survival from first IRE was 2.7 years (95% CI: 1.6, 3.8). Twenty-three participants experienced a total of 34 adverse events in 25 of the 62 procedures (overall complication rate, 40%). One participant (2%), who had an infected biloma after IRE, died fewer than 90 days after the procedure (grade 5 adverse event). Conclusion Irreversible electroporation was effective and relatively safe for colorectal liver metastases 5.0 cm or smaller that were unsuitable for partial hepatectomy, thermal ablation, or further systemic treatment. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Goldberg in this issue.

Entities:  

Year:  2021        PMID: 33724066     DOI: 10.1148/radiol.2021203089

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Gene delivery in adherent and suspension cells using the combined physical methods.

Authors:  Kimia Kardani; Alireza Milani; Azam Bolhassani
Journal:  Cytotechnology       Date:  2022-02-03       Impact factor: 2.058

2.  Early assessment of irreversible electroporation ablation outcomes by analyzing MRI texture: preclinical study in an animal model of liver tumor.

Authors:  Aydin Eresen; Kang Zhou; Chong Sun; Junjie Shangguan; Bin Wang; Liang Pan; Su Hu; Yongsheng Pang; Zigeng Zhang; Robert Minh Nhat Tran; Ajeet Pal Bhatia; Farouk Nouizi; Nadine Abi-Jaoudeh; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 3.  Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors.

Authors:  Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami
Journal:  Diagnostics (Basel)       Date:  2022-05-24

Review 4.  Electroporation and Immunotherapy-Unleashing the Abscopal Effect.

Authors:  Tobias Freyberg Justesen; Adile Orhan; Hans Raskov; Christian Nolsoe; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

Review 5.  Image-Guided Ablation for Colorectal Liver Metastasis: Principles, Current Evidence, and the Path Forward.

Authors:  Yuan-Mao Lin; Iwan Paolucci; Kristy K Brock; Bruno C Odisio
Journal:  Cancers (Basel)       Date:  2021-08-04       Impact factor: 6.639

6.  Recurrent Colorectal Liver Metastases in the Liver Remnant After Major Liver Surgery-IRE as a Salvage Local Treatment When Resection and Thermal Ablation are Unsuitable.

Authors:  Lea Hitpass; Martina Distelmaier; Ulf P Neumann; Wenzel Schöning; Peter Isfort; Sebastian Keil; Christiane K Kuhl; Philipp Bruners; Alexandra Barabasch
Journal:  Cardiovasc Intervent Radiol       Date:  2021-11-10       Impact factor: 2.740

Review 7.  Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist.

Authors:  Javier Torres-Jiménez; Jorge Esteban-Villarrubia; Reyes Ferreiro-Monteagudo; Alfredo Carrato
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

Review 8.  Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin.

Authors:  Giovanni Mauri; Lorenzo Monfardini; Andrea Garnero; Maria Giulia Zampino; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Marco Busso; Carlo Gazzera; Paolo Fonio; Andrea Veltri; Marco Calandri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 9.  Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors.

Authors:  Nana Zhang; Zhuoqun Li; Xuan Han; Ziyu Zhu; Zhujun Li; Yan Zhao; Zhijun Liu; Yi Lv
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.